Date: 2014-03-10
Type of information: Commercialisation agreement
Compound: ATX-101 (proprietary formulation of synthetic sodium deoxycholate)
Company: Bayer HealthCare (Germany) Kythera (USA)
Therapeutic area: Aesthetic area
Type agreement: commercialisation
Action mechanism: ATX-101 is a potential first-in-class injectable drug candidate under clinical investigation for the reduction of localized fat. ATX-101 is a proprietary formulation of synthetic sodium deoxycholate, a well-characterized endogenous compound that is present in the body to promote the natural breakdown of dietary fat. ATX-101 reduces subcutaneous fat through localized fat cell membrane disruption followed by elimination from the treated area. This mechanism may enable a non-surgical alternative for the reduction of unwanted subcutaneous fat. Clinical studies to date have demonstrated that ATX-101 is well tolerated and may effectively reduce localized fat in the submental (under the chin) area.
Disease: reduction of submental fat (double chin)
Details: * On March 10, 2014, Bayer HealthCare and Kythera have announced that Bayer will sell back to Kythera commercial rights to ATX-101 outside of the U.S. and Canada. In 2010, Bayer licensed these rights from Kythera. ATX-101 is a proprietary formulation of a purified synthetic version of deoxycholic acid currently in late-stage development for the reduction of submental fat (double chin).
Financial terms: Under the new agreement, Bayer will receive $ 33 million in Kythera common stock, plus a $ 51 million promissory note, payable no later than 2024 from Kythera. Bayer is also eligible to receive certain long-term sales milestone payments on annual sales outside of the U.S. and Canada.
Latest news:
